Pneumococcal vaccines for sickle cell disease

Risk of invasive pneumococcal disease in children with sickle cell disease in the era of conjugate vaccines: a systematic review of the literature

“…Another licensed PCV formulation, PCV10, that protects against serotypes 1, 5 and 7F in addition to PCV7 serotypes was also licensed at around the same time and implemented in other countries. All three vaccines have led to rapid and sustained declines in IPD caused by the respective vaccine serotypes, in both healthy children and in those with comorbidities, such as SCD (Black et al , ; Davies et al , ; Conklin et al , ). Most childhood IPD cases are now due to non‐PCV serotypes; recent reports have identified differences in infecting serotypes and clinical presentation among children with SCD who develop IPD, as well as a shift in case fatality to older age groups (Martin et al , ).…”

Risk of invasive pneumococcal disease in children with sickle cell disease in the era of conjugate vaccines: a systematic review of the literature

“…Another licensed PCV formulation, PCV10, that protects against serotypes 1, 5 and 7F in addition to PCV7 serotypes was also licensed at around the same time and implemented in other countries. All three vaccines have led to rapid and sustained declines in IPD caused by the respective vaccine serotypes, in both healthy children and in those with comorbidities, such as SCD (Black et al , ; Davies et al , ; Conklin et al , ). Most childhood IPD cases are now due to non‐PCV serotypes; recent reports have identified differences in infecting serotypes and clinical presentation among children with SCD who develop IPD, as well as a shift in case fatality to older age groups (Martin et al , ).…”

Paediatric immunisation and chemoprophylaxis in a Ugandan sickle cell disease clinic

“…High under 5‐year mortality of these children is often associated with infections from encapsulated bacteria, including Streptococcus pneumonia ( S. pneumonia ) , Haemophilus influenza b (Hib) and malaria . Vaccination is a key protective measure against S. pneumonia in SCD …”

Alteration of lymphocyte phenotype and function in sickle cell anemia: Implications for vaccine responses

“…These observations potentially reflect the unique immune environment in individuals with SCA that may influence vaccine reactivity. To date, however, few randomized controlled trials of vaccines have been done among individuals with SCA, including only one trial of pneumococcal vaccine and none of Haemophilus influenzae type B vaccine . Thus, recommendations for the use of these vaccines in SCA are based on efficacy trials done mostly in individuals without SCA .…”

“…To date, however, few randomized controlled trials of vaccines have been done among individuals with SCA, including only one trial of pneumococcal vaccine and none of Haemophilus influenzae type B vaccine . Thus, recommendations for the use of these vaccines in SCA are based on efficacy trials done mostly in individuals without SCA . Although observational studies of the impact of pneumococcal conjugate vaccines in SCA have reported substantial reduction in invasive pneumococcal disease risk , room still exists to improve vaccine outcomes even further to meet protection levels conferred among individuals without SCA .…”

“…Randomized controlled trials of these vaccines in SCA are therefore much needed, especially in sub‐Saharan Africa where the burden of SCA is highest. Insights from these trials will inform optimization of vaccination and booster regimen required to improve the magnitude and duration of vaccine protection against infection in individuals with SCA .…”

Risk of invasive pneumococcal disease in children with sickle cell disease in the era of conjugate vaccines: a systematic review of the literature

“…Another licensed PCV formulation, PCV10, that protects against serotypes 1, 5 and 7F in addition to PCV7 serotypes was also licensed at around the same time and implemented in other countries. All three vaccines have led to rapid and sustained declines in IPD caused by the respective vaccine serotypes, in both healthy children and in those with comorbidities, such as SCD (Black et al , ; Davies et al , ; Conklin et al , ). Most childhood IPD cases are now due to non‐PCV serotypes; recent reports have identified differences in infecting serotypes and clinical presentation among children with SCD who develop IPD, as well as a shift in case fatality to older age groups (Martin et al , ).…”

Paediatric immunisation and chemoprophylaxis in a Ugandan sickle cell disease clinic

“…High under 5‐year mortality of these children is often associated with infections from encapsulated bacteria, including Streptococcus pneumonia ( S. pneumonia ) , Haemophilus influenza b (Hib) and malaria . Vaccination is a key protective measure against S. pneumonia in SCD …”

Alteration of lymphocyte phenotype and function in sickle cell anemia: Implications for vaccine responses

“…These observations potentially reflect the unique immune environment in individuals with SCA that may influence vaccine reactivity. To date, however, few randomized controlled trials of vaccines have been done among individuals with SCA, including only one trial of pneumococcal vaccine and none of Haemophilus influenzae type B vaccine . Thus, recommendations for the use of these vaccines in SCA are based on efficacy trials done mostly in individuals without SCA .…”

“…To date, however, few randomized controlled trials of vaccines have been done among individuals with SCA, including only one trial of pneumococcal vaccine and none of Haemophilus influenzae type B vaccine . Thus, recommendations for the use of these vaccines in SCA are based on efficacy trials done mostly in individuals without SCA . Although observational studies of the impact of pneumococcal conjugate vaccines in SCA have reported substantial reduction in invasive pneumococcal disease risk , room still exists to improve vaccine outcomes even further to meet protection levels conferred among individuals without SCA .…”

“…Randomized controlled trials of these vaccines in SCA are therefore much needed, especially in sub‐Saharan Africa where the burden of SCA is highest. Insights from these trials will inform optimization of vaccination and booster regimen required to improve the magnitude and duration of vaccine protection against infection in individuals with SCA .…”

Risk of invasive pneumococcal disease in children with sickle cell disease in the era of conjugate vaccines: a systematic review of the literature

“…Another licensed PCV formulation, PCV10, that protects against serotypes 1, 5 and 7F in addition to PCV7 serotypes was also licensed at around the same time and implemented in other countries. All three vaccines have led to rapid and sustained declines in IPD caused by the respective vaccine serotypes, in both healthy children and in those with comorbidities, such as SCD (Black et al , ; Davies et al , ; Conklin et al , ). Most childhood IPD cases are now due to non‐PCV serotypes; recent reports have identified differences in infecting serotypes and clinical presentation among children with SCD who develop IPD, as well as a shift in case fatality to older age groups (Martin et al , ).…”

Paediatric immunisation and chemoprophylaxis in a Ugandan sickle cell disease clinic

“…High under 5‐year mortality of these children is often associated with infections from encapsulated bacteria, including Streptococcus pneumonia ( S. pneumonia ) , Haemophilus influenza b (Hib) and malaria . Vaccination is a key protective measure against S. pneumonia in SCD …”

Alteration of lymphocyte phenotype and function in sickle cell anemia: Implications for vaccine responses

“…These observations potentially reflect the unique immune environment in individuals with SCA that may influence vaccine reactivity. To date, however, few randomized controlled trials of vaccines have been done among individuals with SCA, including only one trial of pneumococcal vaccine and none of Haemophilus influenzae type B vaccine . Thus, recommendations for the use of these vaccines in SCA are based on efficacy trials done mostly in individuals without SCA .…”

“…To date, however, few randomized controlled trials of vaccines have been done among individuals with SCA, including only one trial of pneumococcal vaccine and none of Haemophilus influenzae type B vaccine . Thus, recommendations for the use of these vaccines in SCA are based on efficacy trials done mostly in individuals without SCA . Although observational studies of the impact of pneumococcal conjugate vaccines in SCA have reported substantial reduction in invasive pneumococcal disease risk , room still exists to improve vaccine outcomes even further to meet protection levels conferred among individuals without SCA .…”

“…Randomized controlled trials of these vaccines in SCA are therefore much needed, especially in sub‐Saharan Africa where the burden of SCA is highest. Insights from these trials will inform optimization of vaccination and booster regimen required to improve the magnitude and duration of vaccine protection against infection in individuals with SCA .…”